176 related articles for article (PubMed ID: 37343845)
1. Successful treatment of JAK1-associated inflammatory disease.
Fayand A; Hentgen V; Posseme C; Lacout C; Picard C; Moguelet P; Cescato M; Sbeih N; Moreau TRJ; Zhu YYJ; Charuel JL; Corneau A; Deibener-Kaminsky J; Dupuy S; Fusaro M; Hoareau B; Hovnanian A; Langlois V; Le Corre L; Maciel TT; Miskinyte S; Miyara M; Moulinet T; Perret M; Schuhmacher MH; Rignault-Bricard R; Viel S; Vinit A; Soria A; Duffy D; Launay JM; Callebert J; Herbeuval JP; Rodero MP; Georgin-Lavialle S
J Allergy Clin Immunol; 2023 Oct; 152(4):972-983. PubMed ID: 37343845
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
3. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis.
Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
J Dermatol; 2023 Jan; 50(1):e1-e19. PubMed ID: 36412059
[TBL] [Abstract][Full Text] [Related]
4. Individuals with JAK1 variants are affected by syndromic features encompassing autoimmunity, atopy, colitis, and dermatitis.
Horesh ME; Martin-Fernandez M; Gruber C; Buta S; Le Voyer T; Puzenat E; Lesmana H; Wu Y; Richardson A; Stein D; Hodeib S; Youssef M; Kurowski JA; Feuille E; Pedroza LA; Fuleihan RL; Haseley A; Hovnanian A; Quartier P; Rosain J; Davis G; Mullan D; Stewart O; Patel R; Lee AE; Rubinstein R; Ewald L; Maheshwari N; Rahming V; Chinn IK; Lupski JR; Orange JS; Sancho-Shimizu V; Casanova JL; Abul-Husn NS; Itan Y; Milner JD; Bustamante J; Bogunovic D
J Exp Med; 2024 Jun; 221(6):. PubMed ID: 38563820
[TBL] [Abstract][Full Text] [Related]
5. JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis.
Klaeschen AS; Nümm TJ; Herrmann N; Leib N; Maintz L; Sakai T; Wenzel J; Bieber T
J Allergy Clin Immunol; 2021 Jun; 147(6):2202-2212.e8. PubMed ID: 33338537
[TBL] [Abstract][Full Text] [Related]
6. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
Nakashima C; Yanagihara S; Otsuka A
Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
[TBL] [Abstract][Full Text] [Related]
7. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
Ferreira S; Guttman-Yassky E; Torres T
Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
[TBL] [Abstract][Full Text] [Related]
8. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
9. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
[TBL] [Abstract][Full Text] [Related]
10. JAK inhibitors in the treatment of atopic dermatitis.
Chovatiya R; Paller AS
J Allergy Clin Immunol; 2021 Oct; 148(4):927-940. PubMed ID: 34437922
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R
Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
14. JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis.
Wu J; Li L; Zhu Q; Zhang T; Miao F; Cui Z; Dong G; Tai Z; Chen Z
Biomed Pharmacother; 2024 Feb; 171():116167. PubMed ID: 38262152
[TBL] [Abstract][Full Text] [Related]
15. The suitability of treating atopic dermatitis with Janus kinase inhibitors.
Narla S; Silverberg JI
Expert Rev Clin Immunol; 2022 May; 18(5):439-459. PubMed ID: 35377276
[TBL] [Abstract][Full Text] [Related]
16. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
17. JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an
Frede N; Lorenzetti R; Hüppe JM; Janowska I; Troilo A; Schleyer MT; Venhoff AC; Voll RE; Thiel J; Venhoff N; Rizzi M
Front Immunol; 2023; 14():1087986. PubMed ID: 36776828
[TBL] [Abstract][Full Text] [Related]
18. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
[TBL] [Abstract][Full Text] [Related]
19. Baricitinib for the treatment of atopic dermatitis.
Melo A; Carrascosa JM; Torres T
J Dermatolog Treat; 2022 Aug; 33(5):2404-2413. PubMed ID: 34379541
[TBL] [Abstract][Full Text] [Related]
20. Emerging therapies for atopic dermatitis: JAK inhibitors.
Cotter DG; Schairer D; Eichenfield L
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S53-S62. PubMed ID: 29248518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
